Frédéric de Reydet de Vulpillieres

“Successfully delivering therapies to the tens of millions in need will depend on building a sustainable approach that addresses the challenges and opportunities around treatment access at time of approval. In AD this will very much depend on the integration of real-world evidence (RWE) within health care systems to support evidence for approval as well as Health Technology Assessment and funding allocation.”

Project Leader and WorldWide Market Access Director NS at Novartis